Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-eluting stents: beyond the hyperbole.

William L Hunter1

  • 1Angiotech Pharmaceuticals, Inc., 1618 Station St., Vancouver, BC, Canada V6A 1B6. bhunter@angio.com

Advanced Drug Delivery Reviews
|April 8, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Cadaveric Study Addressing the Feasibility of Remote Patient Monitoring Prosthesis for Total Knee Arthroplasty.

The Journal of arthroplasty·2022
Same author

Maxillary sinusitis resulting from ostium plugging by dislodged bone graft: case report.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons·2009
Same author

Drug-eluting stents: an innovative multidisciplinary drug delivery platform.

Advanced drug delivery reviews·2006
Same author

Drug-eluting stents: a multidisciplinary success story.

Advanced drug delivery reviews·2006
Same author

Characterization of perivascular poly(lactic-co-glycolic acid) films containing paclitaxel.

International journal of pharmaceutics·2004
Same author

The characterization of novel polymeric paste formulations for intratumoral delivery.

International journal of pharmaceutics·2004

Drug-eluting stents (DES) significantly reduce repeat procedures by locally delivering drugs, improving outcomes compared to bare metal stents (BMS). These advancements in interventional cardiology have transformed patient care and spurred further research.

Area of Science:

  • Interventional Cardiology
  • Biomedical Engineering
  • Pharmacology

Background:

  • Bare metal stents (BMS) have limitations, including neointimal hyperplasia and restenosis, leading to repeat interventions.
  • Drug-eluting stents (DES) were developed to overcome BMS limitations by locally delivering therapeutic agents.
  • Initial data suggested DES could significantly reduce clinical and economic costs associated with BMS failure.

Purpose of the Study:

  • To evaluate the efficacy of early drug-eluting stents (DES) in reducing restenosis and repeat interventions.
  • To assess the impact of DES on clinical practice and economic factors.
  • To highlight the research spurred by DES technology in stent design and drug delivery.

Main Methods:

  • Analysis of data from large-scale, comparable U.S. pivotal trials.

Related Experiment Videos

  • Comparison of outcomes between DES (CYPHER, TAXUS) and bare metal stents (BMS).
  • Evaluation of key clinical endpoints such as restenosis and need for re-intervention.

    • Main Results:

    • DES demonstrated a significant reduction in failure rates compared to BMS, approximately 4-fold.
    • DES have led to a decreased need for coronary bypass surgery.
    • The success of DES has driven substantial research in drug delivery and restenosis biology.

    Conclusions:

    • Drug-eluting stents represent a major advancement in cardiovascular medicine.
    • DES have positively impacted clinical practice, patient outcomes, and healthcare economics.
    • The development of DES has catalyzed innovation in local drug delivery and stent technology.